ELIOS is a breakthrough laser technology for treating the worlds leading cause of irreversible blindness, Glaucoma. Glaucoma is associated with elevated eye pressure and conventional treatments involve lowering eye pressure with eye medications and/or invasive surgery. ELIOS uses a proprietary laser platform to lower eye pressure by creating 10 ‘microchannels’ in the eye’s natural fluid outflow system that are highly reproducible. ELIOS avoids the need for stents and implants employed by conventional techniques and can reduce or eliminate the need for daily eye drops. ELIOS can be elegantly combined with routine cataract surgery and has a low surgical intensity meaning it can be easily trained and adopted by comprehensive eye doctors as well as glaucoma specialists.
Clinical data showing the long-term outcomes with ELIOS were recently published and showed a >20% reduction in eye pressure over 8yr follow-up period with no serious safety events recorded. The ELIOS pivotal trial (FDA) is currently underway in the US with recruitment on track and outcomes expected late 2023. To intensify its commercialization and reference account strategy in EU (where ELIOS is already licensed for use), the company has expanded its commercial and medical functions. ELIOS Vision, Inc. strengthened its IP position recently with 4 new patents and further patents pending.